Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 5,354 matching trials from the live ClinicalTrials.gov search.

Filters: Milwaukee, Wisconsin Clear all

Conditions: Lung Transplantation
Interventions: OCS Lung Preservation; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Pulmonary Embolism
Interventions: FlowTriever System, Anticoagulation Agents; Device · Drug
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 42
States / cities: Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more

Conditions: Fabry Disease
Interventions: migalastat hydrochloride, agalsidase; Drug · Biological
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 16 Years to 74 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Decatur, Georgia + 5 more

Conditions: Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, CNS Tumors
Interventions: Allogeneic HCT, Donor NK Cell Infusion; Procedure · Drug
Lead sponsor: Monica Thakar; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions: Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 309
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 230 more

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 227
States / cities: Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more

Conditions: Asthma, Wheezing
Interventions: Azithromycin, Prednisolone, Placebo Azithromycin, Placebo Prednisolone; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Months to 71 Months
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 16
States / cities: Tucson, Arizona • Oakland, California • San Francisco, California + 11 more

Conditions: Postoperative Hypoparathyroidism, Thyroid Disease, Thyroid Neoplasms, Thyroid Cancer
Interventions: NIRAF Detection Technology; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 99 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 90
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 73 more

Conditions: Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
Interventions: Epacadostat, Pembrolizumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 351
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 209 more

Conditions: B-cell Malignancies, Cancer
Interventions: MEDI-551, Rituximab; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Washington D.C., District of Columbia + 10 more

Conditions: Breast Cancer
Interventions: Mini rTG OMEGA-3 Fish Oil; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: IVA337, Placebo; Drug
Lead sponsor: Inventiva Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 194
States / cities: Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more

Conditions: Gastroparesis, Gastroparesis-like Syndrome
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 8 Years to 25 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • Columbus, Ohio • El Paso, Texas + 2 more

Conditions: Critical Limb Ischemia
Interventions: Lutonix DCB, Uncoated PTA Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 33
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Bradenton, Florida + 28 more

Conditions: Metastatic Cancer
Interventions: radiation therapy, surgery, WBRT; Radiation · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2014
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 27 more

Conditions: HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Interventions: HB-201 IV; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: cisplatin, paclitaxel, surgical procedure; Drug · Procedure
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 28
States / cities: Chicago, Illinois • Evanston, Illinois • Peoria, Illinois + 18 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Vision Research Foundation; Other
Eligibility: 30 Weeks to 36 Weeks
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Palo Alto, California • Miami, Florida + 14 more

Conditions: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Interventions: AZD5312; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Sarasota, Florida • Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 1,140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 94
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 91 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: motavizumab (MEDI-524), palivizumab; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: Up to 24 Months
Enrollment: 6,635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 120
States / cities: Birmingham, Alabama • Pike Road, Alabama • Phoenix, Arizona + 98 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 55
States / cities: Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more

Conditions: Acute Pain
Interventions: IV Acetaminophen, IV Control; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 1 Day to 2 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 22
States / cities: Birmingham, Alabama • Orange, California • San Diego, California + 19 more

Search by objective public record fields.

OCS Lung System EXPAND II Trial

The PEERLESS II Study

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies

Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

GpCRC Pediatric Gastroparesis Registry 2

Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

Model 4296 Left Ventricular (LV) Lead Chronic Performance Study

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients